Haleon has commenced the phased rollout of its new corporate identity across Nigeria, updating branding on product packaging and corporate materials as it completes its transition to a standalone consumer healthcare company.
The development, disclosed in a statement dated June 12, 2026, follows the company's demerger from GSK plc in July 2022. Haleon was created after GSK separated its Consumer Healthcare business, distributing approximately 80% of its 68% stake in the business to GSK shareholders. Prior to the separation, the Consumer Healthcare business had operated as a joint venture between GSK and Pfizer Inc., with GSK holding a controlling 68% interest.
Himanshu Raj, General Manager for Sub-Saharan Africa at Haleon, said the transition is strictly a branding update designed to align products and operations with the Haleon corporate identity. He emphasised that the exercise will not affect the formulation, safety, quality, or effectiveness of any products.
“The trusted products they rely on remain the same in quality, formulation and effectiveness,” Raj stated. He added that the company's local manufacturing partnership with **Fidson Healthcare** continues to support the availability of high-quality healthcare products across the country.
Products already being manufactured and distributed under the new Haleon identity through the Fidson partnership include Panadol Extra 100s and Panadol Pain & Fever 100s. **Sensodyne Rapid Action** will begin carrying the Haleon branding from mid-June, while Andrews Liver Salts is expected to transition later this year. Other products, including Otrivin, Voltaren, Cac 1000, Macleans, and additional Sensodyne variants, will adopt the new branding in phases.
The rollout comes amid ongoing adjustments in Nigeria's pharmaceutical market following GSK's decision to exit direct operations in the country in 2023. That exit contributed to significant price increases for several pharmaceutical products, with some medicines reportedly experiencing price hikes of up to 1,000%. The combination of rising inflation, foreign exchange pressures, and supply chain challenges has placed additional strain on medicine affordability and accessibility for many Nigerians.
